Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 4/27/2021 Combining AstraZeneca’s ‘good’ cholesterol booster with PCSK9 inhibition shows promise in heart disease by Angus Liu | Apr 21, 2021 3:00pm The drug, dubbed MEDI5884, is designed to neutralize a circulating enzyme called endothelial lipase. The protein regulates […]
Search Results for 'PCSK9 '
Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent
Posted in Atherogenic Processes & Pathology, Drug Delivery Platform Technology, Exosomes: Natural Carriers for siRNA Delivery, FDA Regulatory Affairs, Frontiers in Cardiology and Cardiovascular Disorders, Gene Therapy & Gene Editing Development, Genome Biology, Genomics Pharmacy, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease on November 18, 2019| Leave a Comment »
FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease
Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease on December 1, 2017| Leave a Comment »
FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]
19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines
Posted in FDA Regulatory Affairs, New Drug Approval, Personalized and Precision Medicine & Genomic Research on March 2, 2021| Leave a Comment »
19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines Reporter: Aviva Lev-Ari, PhD, RN 2020 DRUG APPROVALS 19 of the 49 new therapeutic molecular entities FDA approved in 2020 — as well as a new cell-based therapy — are […]
NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5
Posted in on June 7, 2022|
Original Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the original e-Books in […]
Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic
Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease, Vascular Diseases, tagged Atherosclerosis, Cholesterol, LDL, PCSK9 inhibitors, statins on December 29, 2016| Leave a Comment »
Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/25/2019 https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active While nearly 10% of middle-age adults in China have high risk for cardiovascular disease, only 0.6% of these high-risk individuals use statins and 2.4% […]
A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab) a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway
Posted in Acute Myocardial Infarction, Cardiovascular Research, Frontiers in Cardiology and Cardiovascular Disorders, Heart Failure (HF), inflammation independent of lipid levels, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, Stroke, Vascular Diseases, tagged Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), human monoclonal antibody targeting the interleukin-1beta innate immunity pathway on April 6, 2018| Leave a Comment »
A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]